FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249406961> ?p ?o ?g. }

• W4249406961 endingPage "3242" @default.
• W4249406961 startingPage "3242" @default.
• W4249406961 abstract "Abstract Co-expression of immune checkpoint receptors (ICRs) PD-1, TIM-3, and LAG-3 characterizes chronically activated and exhausted tumor-infiltrating T cells (TILs), suggesting their targeting may have applicability for the treatment of multiple cancer types. We previously reported improved tumor control in various syngeneic and humanized mouse models when treated with a combination of TSR-042 (αPD-1), TSR-022 (αTIM-3), and TSR-033 (αLAG-3) as compared to single or double combinations. Here, we are characterizing TILs from ovarian cancer tissues and their functional response to triple combination treatment. Immune profiling using flow cytometry confirmed expression of all three ICRs on TILs isolated from primary resections of ovarian cancer. Ex vivo re-stimulation of immune infiltrates with S. aureus enterotoxin B in presence of ICR-targeting antibodies led to increased secretion of IFN-γ and IL-2 when treated with TSR-042. Notably, triple combination of TSR-042, TSR-022, and TSR-033 further amplified cytokine release, indicating more effective TIL reinvigoration. To further understand the differential effects of triple combination treatment over PD-1 blockade, we analyzed αCD3/αCD28-stimulated and antibody-treated ovarian cancer TILs on a single cell level using a microfluidic IsoCode chip technology that allows for parallel detection and quantification of 32 secreted proteins from live single cells. Combining the amount of each protein secreted by polyfunctional T cells (co-secreting two or more proteins per cell) with the frequency of such cells results in a measurement of polyfunctional strength (PSI), a unique IsoCode-enabled metric that has been associated with improved response to ICR inhibition. TSR-042 increased the PSI of CD4+ and CD8+ TILs 1.4 and 1.5-fold over isotype control treatment. Importantly, triple combination treatment was able to significantly increase the PSI of both subsets by 2.9 and 3.7-fold, respectively (p &lt; 0.001). For CD8+ TILs, this increase was mainly driven by an increase in the frequency of polyfunctional subsets, while for CD4+ TILs, the absolute amounts of secreted cytokines had a larger impact. Interestingly, both classical effector cytokines like Granzyme B and IFN-γ as well as other secreted factors like chemoattractant factors, implicated in the recruitment of multiple immune cell subsets to tumor tissue, contributed to T cell polyfunctionality. Taken together, triple ICR blockade targeting PD-1, TIM-3, and LAG-3 reinvigorated ovarian cancer TILs more effectively than PD-1 inhibition alone. This was mediated by increasing T cell polyfunctionality, which has been associated with improved anti-tumor activity and response to ICR inhibition. This data further supports the concept of triple combination checkpoint blockade as a treatment option for ovarian cancer. Citation Format: Johanna K. Kaufmann, Brianna Flynn, Kevin Morse, Maria C. Speranza, Jing Zhou, Sridhar Ramaswamy, Sean Mackay, Kevin G. Coleman. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 reinvigorates ovarian cancer-infiltrating T cells by increasing T cell polyfunctionality and effector function [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3242." @default.
• W4249406961 created "2022-05-12" @default.
• W4249406961 creator A5012011761 @default.
• W4249406961 creator A5015038830 @default.
• W4249406961 creator A5029504198 @default.
• W4249406961 creator A5032742387 @default.
• W4249406961 creator A5043685783 @default.
• W4249406961 creator A5049884419 @default.
• W4249406961 creator A5064174665 @default.
• W4249406961 creator A5050196869 @default.
• W4249406961 date "2019-07-01" @default.
• W4249406961 modified "2023-09-27" @default.
• W4249406961 title "Abstract 3242: Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 reinvigorates ovarian cancer-infiltrating T cells by increasing T cell polyfunctionality and effector function" @default.
• W4249406961 doi "https://doi.org/10.1158/1538-7445.am2019-3242" @default.
• W4249406961 hasPublicationYear "2019" @default.
• W4249406961 type Work @default.
• W4249406961 citedByCount "3" @default.
• W4249406961 countsByYear W42494069612021 @default.
• W4249406961 countsByYear W42494069612022 @default.
• W4249406961 crossrefType "journal-article" @default.
• W4249406961 hasAuthorship W4249406961A5012011761 @default.
• W4249406961 hasAuthorship W4249406961A5015038830 @default.
• W4249406961 hasAuthorship W4249406961A5029504198 @default.
• W4249406961 hasAuthorship W4249406961A5032742387 @default.
• W4249406961 hasAuthorship W4249406961A5043685783 @default.
• W4249406961 hasAuthorship W4249406961A5049884419 @default.
• W4249406961 hasAuthorship W4249406961A5050196869 @default.
• W4249406961 hasAuthorship W4249406961A5064174665 @default.
• W4249406961 hasConcept C121608353 @default.
• W4249406961 hasConcept C126322002 @default.
• W4249406961 hasConcept C148125776 @default.
• W4249406961 hasConcept C159654299 @default.
• W4249406961 hasConcept C170493617 @default.
• W4249406961 hasConcept C203014093 @default.
• W4249406961 hasConcept C2776090121 @default.
• W4249406961 hasConcept C2777367678 @default.
• W4249406961 hasConcept C2777701055 @default.
• W4249406961 hasConcept C2778468042 @default.
• W4249406961 hasConcept C2780427987 @default.
• W4249406961 hasConcept C2780851360 @default.
• W4249406961 hasConcept C502942594 @default.
• W4249406961 hasConcept C51785407 @default.
• W4249406961 hasConcept C553184892 @default.
• W4249406961 hasConcept C55493867 @default.
• W4249406961 hasConcept C71924100 @default.
• W4249406961 hasConcept C86803240 @default.
• W4249406961 hasConcept C8891405 @default.
• W4249406961 hasConceptScore W4249406961C121608353 @default.
• W4249406961 hasConceptScore W4249406961C126322002 @default.
• W4249406961 hasConceptScore W4249406961C148125776 @default.
• W4249406961 hasConceptScore W4249406961C159654299 @default.
• W4249406961 hasConceptScore W4249406961C170493617 @default.
• W4249406961 hasConceptScore W4249406961C203014093 @default.
• W4249406961 hasConceptScore W4249406961C2776090121 @default.
• W4249406961 hasConceptScore W4249406961C2777367678 @default.
• W4249406961 hasConceptScore W4249406961C2777701055 @default.
• W4249406961 hasConceptScore W4249406961C2778468042 @default.
• W4249406961 hasConceptScore W4249406961C2780427987 @default.
• W4249406961 hasConceptScore W4249406961C2780851360 @default.
• W4249406961 hasConceptScore W4249406961C502942594 @default.
• W4249406961 hasConceptScore W4249406961C51785407 @default.
• W4249406961 hasConceptScore W4249406961C553184892 @default.
• W4249406961 hasConceptScore W4249406961C55493867 @default.
• W4249406961 hasConceptScore W4249406961C71924100 @default.
• W4249406961 hasConceptScore W4249406961C86803240 @default.
• W4249406961 hasConceptScore W4249406961C8891405 @default.
• W4249406961 hasIssue "13_Supplement" @default.
• W4249406961 hasLocation W42494069611 @default.
• W4249406961 hasOpenAccess W4249406961 @default.
• W4249406961 hasPrimaryLocation W42494069611 @default.
• W4249406961 hasRelatedWork W1566117310 @default.
• W4249406961 hasRelatedWork W1607301590 @default.
• W4249406961 hasRelatedWork W2342912071 @default.
• W4249406961 hasRelatedWork W2797580541 @default.
• W4249406961 hasRelatedWork W2820886885 @default.
• W4249406961 hasRelatedWork W2955970465 @default.
• W4249406961 hasRelatedWork W3003310139 @default.
• W4249406961 hasRelatedWork W3127468120 @default.
• W4249406961 hasRelatedWork W3204147903 @default.
• W4249406961 hasRelatedWork W4309469576 @default.
• W4249406961 hasVolume "79" @default.
• W4249406961 isParatext "false" @default.
• W4249406961 isRetracted "false" @default.
• W4249406961 workType "article" @default.